✦ LIBER ✦

Progression-free survival as an end-point in solid tumours – Perspectives from clinical trials and clinical practice

✍ Scribed by Robinson, Andrew G.; Booth, Christopher M.; Eisenhauer, Elizabeth A.

Book ID: 125821811
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 375 KB
Volume: 50
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2014.05.024

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Disease-free survival as an end-point in

Disease-free survival as an end-point in the treatment of solid tumours – Perspectives from clinical trials and clinical practice

✍ Robinson, Andrew G.; Booth, Christopher M.; Eisenhauer, Elizabeth A. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 326 KB

Progression-free survival as an end-poin

Progression-free survival as an end-point in clinical trials of biotherapeutic agents

✍ Lothar Bergmann; Steven Hirschfeld; Charles Morris; Sergio Palmeri; Andrew Stone 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 141 KB

The need for levodopa as an end point of

The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α-tocopherol

✍ Dr. Peter LeWitt; David Oakes; Lu Cui 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 693 KB

## Abstract Progression of Parkinson's disease (PD) can be detected through changes in clinical ratings or disability assessments. A clinical trial, Deprenyl and Alpha‐Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP), used a novel study end point: increase in parkinsonian disability to th

Phase II study of first-line bortezomib

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

✍ O’Brien, Mary E.R.; Gaafar, Rabab M.; Popat, Sanjay; Grossi, Francesco; Price, A 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 444 KB